WB, IP
Vir
Endogenous
25-31
Rabbit
#P0DTC3
43740569
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
Storage
Specificity / Sensitivity
Species Reactivity:
Virus
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ile232 of SARS-CoV-2 ORF3a protein. Antibodies are purified by protein A and peptide affinity chromatography.
Background
SARS-CoV-2 ORF3a is the largest of the SARS-CoV-2 accessory proteins containing three amino-terminal transmembrane domains localized to the plasma membrane and perinuclear regions including the golgi apparatus (1). It contains several functional domains including a TRAF3 binding motif, a caveolin-binding motif, a tyrosine-sorting motif, and a diacidic motif (2). SARS-CoV ORF3a was shown to regulate apoptotic and necrotic cell death and inhibit late stages of autophagy by inhibiting fusion of the autophagosome and lysosome (3-5). SARS-CoV-2 ORF3a was also found to inhibit late stages of autophagy by inhibiting fusion of the autophagosome and lysosome through association with components of the homotypic fusion and protein sorting HOPS complex (6-8). It is thought that SARS-CoV-2 can form ion channels that regulates viral release (9). In addition, it can regulate several aspects of innate immune responses, including TRAF3 signaling, activation of NF-κB, and production of inflammatory cytokines (10,11).
α
- Redondo, N. et al. (2021) Front Immunol 12, 708264.
- Issa, E. et al. (2020) mSystems 5, e00266-20. doi: 10.1128/mSystems.00266-20.
- Yue, Y. et al. (2018) Cell Death Dis 9, 904.
- Ren, Y. et al. (2020) Cell Mol Immunol 17, 881-883.
- Law, P.T.W. et al. (2005) J Gen Virol 86, 1921-1930.
- Zhang, Y. et al. (2021) Cell Discov 7, 31.
- Miao, G. et al. (2021) Dev Cell 56, 427-442.e5.
- Qu, Y. et al. (2021) Front Cell Dev Biol 9, 716208.
- Marquez-Miranda, V. et al. (2020) bioRxiv, 10.22.349522. doi: 10.1101/2020.10.22.349522.
- Su, C.M. et al. (2021) Sci Rep 11, 13464.
- Siu, K.L. et al. (2019) FASEB J 33, 8865-8877.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IP: Immunoprecipitation
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.
